Chimeric antigen receptor (CAR) T cell therapy represents a significant breakthrough in cancer treatment, offering a new approach to enhance the immune system’s ability to fight cancer. The therapy involves engineering T cells with synthetic receptors called CARs to recognize and destroy cancer cells. Despite significant advancements in the field, most production of these T…
Medulloblastoma is a common and aggressive type of brain tumor in children, consisting of four molecular subgroups. Traditional methods of treatment with surgery, radiotherapy and chemotherapy result in an incomplete response with serious side effects. Immunotherapy using the blockade of immune checkpoints such as PD-1, PD-L1 and CTLA4 has increased its prominence in solid tumor…
Authors and Affiliations:Cláudia Martins1,2,3, Catarina Pacheco1,2,4, Catarina Moreira-Barbosa1,2,3, Ângela Marques-Magalhães1,2,3, Sofia Dias1,2,3, Marco Araújo1,2, Maria J. Oliveira1,2,3, Bruno Sarmento1,2,4* 1i3S – Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Rua Alfredo Allen 208, 4200-393 Porto, Portugal. 2INEB – Instituto Nacional de Engenharia Biomédica, Universidade do Porto, Rua Alfredo Allen 208, 4200-393 Porto, Portugal…
The aggressiveness of melanoma and lack of effective therapies incite the discovery of novel strategies. Recently, a new dual acting hybrid molecule (HM), combining a triazene and a ʟ-tyrosine analogue, was synthesized. HM was designed to specifically be activated by tyrosinase, the enzyme involved in melanin biosynthesis and overexpressed in melanoma. HM displayed remarkable superior…
Authors and Affiliations: Francisco Silva1,*, Carolina Mendes1, Alice D’Onofrio1, Maria Paula Cabral Campello1,2, Fernanda Marques1,2, Teresa Pinheiro2,3, Kyle Gonçalves1, Sérgio Figueiredo4,5, Lurdes Gano1,2, Mauro Ravera6, Elisabetta Gabano7, António Paulo1,2 1. Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, Campus Tecnológico e Nuclear, Estrada Nacional 10, Km 139.7, 2695-066 Bobadela LRS, Portugal….
Authors and Affiliations: Sara Monteiro-Reis1,2*, Vera Miranda-Gonçalves1,3*, Catarina Guimarães-Teixeira1, Cláudia Martins-Lima1, João Lobo1,3,4, Diana Montezuma1, Paula C. Dias1,4, Helene Neyret-Kahn5, Isabelle Bernard-Pierrot5, Rui Henrique1,3,4, Carmen Jerónimo1,3 1. Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/RISE@CIIPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (P.CCC Raquel…
The One Step Nucleic Acid Amplification (OSNA) is a recent technique for sentinel lymph nodes staging in breast cancer (BC). After OSNA assay, instead of being discarded, the residual OSNA lysate can also be used for gene expression studies, being the potentially ideal sample to search for new biomarkers. The aim of our study was…
An international team, led by Carla Oliveira, from the Institute for Research and Innovation in Health of University of Porto (i3S), published a study in the Lancet Oncology journal identifying the alterations in the CDH1 gene that specifically increase the risk of developing cancers associated to Hereditary Diffuse Gastric Cancer (HDGC) syndrome. This study has…
Cervical cancer (CC) is considered the 4th most common cause of death in women worldwide, with over 99% of cases related to human papilloma virus (HPV) infection. The development of this pathology is related to the expression of the HPV E6 and E7 proteins, since they can interfere with the cellular regulatory mechanisms potentiated by…
Most of the functions ascribed to the Golgi are strongly associated with cellular events central to cancer initiation and progression. However, we still do not fully understand if and how this enigmatic organelle steers the “weal” of a cancer cell and how it contributes to its fate. This article published by our group from CBIOS,…